TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03441113

Intervention type: DRUG
Group type: OTHER
Intervention: MMB
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: MMB
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: MMB
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: MMB
Description: Tablet(s) administered orally once daily
Study: NCT03694015

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SUPR
Description: simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VMAT
Description: volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
Study: NCT02304328

Intervention type: OTHER
Intervention: Clinical assessment
Description: Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes

Intervention type: OTHER
Intervention: Clinical assessment
Description: Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
Study: NCT02406118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
Study: NCT00579540

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Seed Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Seed Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Seed Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
Study: NCT03766893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine / Naloxone Oral Product
Description: To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable naltrexone
Description: To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
Study: NCT04759950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
Study: NCT01187810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
Study: NCT02970786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 68Ga-NODAGA-E(c[RGDyK])2
Description: Following one injection of 68Ga-NODAGA-E(c\[RGDyK\])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
Study: NCT00661713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Study: NCT00661713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02735707

Intervention type: OTHER
Group type: OTHER
Intervention: No endothelial modulator
Description: No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.

Intervention type: OTHER
Group type: OTHER
Intervention: No Immune Modulator for Influenza
Description: No immune modulating agent intended to be active against influenza is to be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib
Description: Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).

Intervention type: OTHER
Group type: OTHER
Intervention: No antiviral agent for COVID-19
Description: No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered

Intervention type: DRUG
Group type: OTHER
Intervention: Nirmatrelvir/ritonavir
Description: Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.

Intervention type: DRUG
Group type: OTHER
Intervention: Remdesivir
Description: Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.

Intervention type: DRUG
Group type: OTHER
Intervention: Nirmatrelvir/ritonavir + remdesivir
Description: Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Study: NCT04480333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: NA-831 - 0.10 mg/kg
Description: NA-831 in nanoparticle inhalation formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 0.10 mg/kg
Description: Placebo in nanoparticle inhalation formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: NA-831 - 0.20 mg/kg
Description: NA-831 in nanoparticle inhalation formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 0.20 mg/kg
Description: Placebo in nanoparticle inhalation formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GS-5734 - 1.00 mg/kg
Description: GS-5734 in nanoparticle inhaled formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 1.00 mg/kg
Description: Placebo in nanoparticle inhalation formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GS-5734 - 2.00 mg/kg
Description: GS-5734 in nanoparticle inhaled formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 2.00 mg/kg
Description: Placebo in nanoparticle inhaled formulation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
Description: The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.10 mg + 1.00 mg/kg
Description: The combined placebo are in nanoparticle inhaled formulation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)
Description: The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.20 mg + 2.00 mg/kg
Description: Placebo 0.10 mg + 1.00 mg/kg
Study: NCT02607280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
Study: NCT03729323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nursing Consultation
Description: In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
Study: NCT03203174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Microneedle
Description: Flat roller with no needles on the roller

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin type A will be applied to the palm

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin type A will be applied to the palm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline applied to the palm

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline applied to the palm
Study: NCT02272153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg refined grain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg refined grain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg refined grain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg Whole Grain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg Whole Grain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg Whole Grain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Refined grain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Refined grain
Study: NCT00661713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00878319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Description: Antero-latero or posterior surgical approach using dynamic compression plate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical
Description: Sugartong splint followed by transition to functional co-aptation brace
Study: NCT03044587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
Description: Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w

Intervention type: DRUG
Group type: OTHER
Intervention: Arm Cisplatin + Gemcitabine (Arm B)
Description: Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
Study: NCT04271566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program
Description: A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
Study: NCT02882841

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies, stool and blood collection
Study: NCT02774564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: Nebicapone tablets 50 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: Nebicapone tablets 50 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: Nebicapone tablets 50 mg, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebicapone matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebicapone matching placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebicapone matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sinemet®
Description: Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
Study: NCT04717947

Intervention type: PROCEDURE
Intervention: Interval between NAT and surgery
Description: Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.

Intervention type: PROCEDURE
Intervention: Interval between NAT and surgery
Description: Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
Study: NCT01618578

Intervention type: PROCEDURE
Intervention: rubber hand illusion
Description: There were three consecutive trials of the RHI:~1. one control trial: asynchronous condition (3 Min.)~2. two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)

Intervention type: PROCEDURE
Intervention: rubber hand illusion
Description: There were three consecutive trials of the RHI:~1. one control trial: asynchronous condition (3 Min.)~2. two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)

Intervention type: PROCEDURE
Intervention: rubber hand illusion
Description: There were three consecutive trials of the RHI:~1. one control trial: asynchronous condition (3 Min.)~2. two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)
Study: NCT02128698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-assisted exercise
Description: Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted exercise
Description: Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual exercise
Description: Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual exercise
Description: Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
Study: NCT02638233

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)